WCM Investment Management LLC raised its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 6.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 102,992 shares of the biotechnology company's stock after buying an additional 5,906 shares during the quarter. WCM Investment Management LLC owned about 0.18% of Repligen worth $13,740,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of RGEN. Price T Rowe Associates Inc. MD lifted its holdings in shares of Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after purchasing an additional 594,189 shares in the last quarter. Groupama Asset Managment lifted its holdings in shares of Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock valued at $58,142,000 after purchasing an additional 400,680 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Repligen during the 4th quarter valued at about $53,428,000. Finally, Raymond James Financial Inc. bought a new position in shares of Repligen during the 4th quarter valued at about $52,492,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
RGEN has been the topic of several recent analyst reports. Canaccord Genuity Group cut their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a report on Tuesday, April 29th. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective on the stock. Finally, JPMorgan Chase & Co. cut their price objective on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $172.83.
Get Our Latest Stock Analysis on Repligen
Repligen Stock Up 0.3%
Shares of Repligen stock traded up $0.40 on Friday, reaching $127.36. 208,766 shares of the company were exchanged, compared to its average volume of 729,442. Repligen Corporation has a one year low of $102.97 and a one year high of $182.52. The company has a market capitalization of $7.16 billion, a price-to-earnings ratio of -283.02, a PEG ratio of 3.65 and a beta of 1.11. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average of $126.70 and a 200 day moving average of $139.87.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The company had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. During the same quarter in the prior year, the business posted $0.28 EPS. The business's revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More

Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.